Relapse assessment following allogeneic SCT in patients with MDS and AML
Standard
Relapse assessment following allogeneic SCT in patients with MDS and AML. / Christopeit, Maximilian; Kröger, Nicolaus; Haferlach, Torsten; Bacher, Ulrike.
in: ANN HEMATOL, Jahrgang 93, Nr. 7, 01.07.2014, S. 1097-110.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Relapse assessment following allogeneic SCT in patients with MDS and AML
AU - Christopeit, Maximilian
AU - Kröger, Nicolaus
AU - Haferlach, Torsten
AU - Bacher, Ulrike
PY - 2014/7/1
Y1 - 2014/7/1
N2 - Options to pre-emptively treat impending relapse of myelodysplastic syndromes (MDS) and acute myeloid leukaemia (AML) after allogeneic haematopoietic stem cell transplantation (allo-SCT) continuously increase. In recent years, the spectrum of diagnostic methods and parameters to perform post-transplant monitoring in patients with AML and MDS has grown. Cytomorphology, histomorphology, and chimaerism analysis are the mainstay in any panel of post-transplant monitoring. This may be individually combined with multiparameter flow cytometry (MFC) for the detection of residual cells with a leukaemia phenotype and quantitative real-time polymerase chain reaction (RQ-PCR) to assess gene expression, e.g., of WT1 or the residual mutation load (e.g., in case of an NPM1 mutation). Data evaluating the aforementioned methods alone or in combination are discussed in this review with particular emphasis on data pointing towards their suitability to steer pre-emptive post-transplant interventions such as immunotherapy, chemotherapy or therapy with demethylating agents.
AB - Options to pre-emptively treat impending relapse of myelodysplastic syndromes (MDS) and acute myeloid leukaemia (AML) after allogeneic haematopoietic stem cell transplantation (allo-SCT) continuously increase. In recent years, the spectrum of diagnostic methods and parameters to perform post-transplant monitoring in patients with AML and MDS has grown. Cytomorphology, histomorphology, and chimaerism analysis are the mainstay in any panel of post-transplant monitoring. This may be individually combined with multiparameter flow cytometry (MFC) for the detection of residual cells with a leukaemia phenotype and quantitative real-time polymerase chain reaction (RQ-PCR) to assess gene expression, e.g., of WT1 or the residual mutation load (e.g., in case of an NPM1 mutation). Data evaluating the aforementioned methods alone or in combination are discussed in this review with particular emphasis on data pointing towards their suitability to steer pre-emptive post-transplant interventions such as immunotherapy, chemotherapy or therapy with demethylating agents.
KW - Animals
KW - Hematopoietic Stem Cell Transplantation
KW - Humans
KW - Leukemia, Myeloid, Acute
KW - Mutation
KW - Myelodysplastic Syndromes
KW - Recurrence
KW - Transplantation, Homologous
U2 - 10.1007/s00277-014-2046-8
DO - 10.1007/s00277-014-2046-8
M3 - SCORING: Journal article
C2 - 24671364
VL - 93
SP - 1097
EP - 1110
JO - ANN HEMATOL
JF - ANN HEMATOL
SN - 0939-5555
IS - 7
ER -